JPMorgan raised the firm’s price target on IGM Biosciences to $12 from $11 and keeps a Neutral rating on the shares post the Q2 report. The analyst cites the company’s clinical execution across its pipeline with positive enrollment updates for the target bump.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- IGMS Earnings this Week: How Will it Perform?
- IGM Biosciences Refocuses Genzyme Collaboration on Immunology
- RBC says NEJM publication of anti-CD38 mAb approach helps to de-risk IGM’s ‘2644
- IGM Biosciences participates in a conference call with JPMorgan